| Name | Title | Contact Details |
|---|
Cornerstone Family Healthcare is a comprehensive Hudson Valley medical care provider, offering urgent care, preventative care, womens health, pediatrics and more.
Eisai Inc. is a U.S. pharmaceutical subsidiary of Tokyo-based Eisai Co., Ltd., a research-based human health care (hhc) company that discovers, develops and markets products throughout the world.
Harpoon Therapeutics is a clinical-stage immuno-oncology company developing a novel class of T cell engagers that harness the power of the body`s immune system to treat patients suffering from cancer and other diseases. T cell engagers are engineered proteins that direct a patient`s own T cells to kill target cells that express specific proteins, or antigens, carried by the target cells. Using its proprietary Tri-specific T cell Activating Construct (TriTAC®) platform, Harpoon is developing a pipeline of novel TriTACs initially focused on the treatment of solid tumors and hematologic malignancies. Harpoon has also developed a proprietary ProTriTAC™ platform, which applies a prodrug concept to its TriTAC platform to create a therapeutic T cell engager that remains inactive until it reaches the tumor. Harpoon`s third proprietary technology platform, extended release TriTAC-XR, is designed to mitigate cytokine release syndrome.
"Santa Cruz Nutritionals is the world's leading manufacturer of enhanced confectionery delivery systems for the functional food and supplement, or ""nutraceutical"" market. Using its unique food science expertise and proprietary processes the company has"
At Santen, we`re innovating therapies to improve the quality of life for patients worldwide. Our single focus in ophthalmology enables us to challenge unmet needs in the field—through passionate research, successful collaboration, and clarity of commitment. With over 120 years of investigative insight, Santen remains committed to the discovery, exploration, and development of ophthalmic therapies. Now, and into the future. As a global company, Santen is often expanding to accommodate new and evolving initiatives in ophthalmic research, regulatory management, production, marketing, or distribution. Our clinical development network now spans three continents, with centers in EMEA (Europe, the Middle East and Africa), Japan, and the United States.